You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameIsoflurophate
Accession NumberDB00677  (APRD00763)
TypeSmall Molecule
GroupsApproved, Withdrawn
DescriptionAn irreversible cholinesterase inhibitor with actions similar to those of echothiophate. It is a powerful miotic used mainly in the treatment of glaucoma. Its vapor is highly toxic and it is recommended that only solutions in arachis oil be used therapeutically. (From Martindale, The Extra Pharmacopoeia, 29th ed, p1330)
Structure
Thumb
Synonyms
DFP
Diisopropoxyphosphoryl Fluoride
Diisopropyl fluorophosphate
Diisopropyl Fluorophosphonate
Diisopropyl Phosphofluoridate
Diisopropyl Phosphorofluoridate
Diisopropylfluorophosphate
Diisopropylfluorophosphoric acid ester
Diisopropylphosphofluoridate
Diisopropylphosphorofluoridate
Fluorodiisopropyl Phosphate
Fluorostigmine
Isofluorphate
Isoflurophate
Isoflurophosphate
Isopropyl fluophosphate
Isopropyl Phosphorofluoridate
Neoglaucit
O,O'-diisopropyl phosphoryl fluoride
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
DiflupylNot Available
FloroprylMerck
FluoprylMerck
Brand mixturesNot Available
SaltsNot Available
Categories
UNII12UHW9R67N
CAS number55-91-4
WeightAverage: 184.1457
Monoisotopic: 184.066459031
Chemical FormulaC6H14FO3P
InChI KeyMUCZHBLJLSDCSD-UHFFFAOYSA-N
InChI
InChI=1S/C6H14FO3P/c1-5(2)9-11(7,8)10-6(3)4/h5-6H,1-4H3
IUPAC Name
bis(propan-2-yl) fluorophosphonate
SMILES
CC(C)OP(F)(=O)OC(C)C
Pharmacology
IndicationFor use in the eye to treat certain types of glaucoma and other eye conditions, such as accommodative esotropia.
Structured Indications Not Available
PharmacodynamicsIsoflurophate is used as ocular drops in the treatment of chronic glaucoma. Isoflurophate is an organophosphorus compound that acts as an irreversible cholinesterase inhibitor. As such, it displays parasympathomimetic effects. Isoflurophate is used in the eye to treat certain types of glaucoma and other eye conditions, such as accommodative esotropia. They may also be used in the diagnosis of certain eye conditions, such as accommodative esotropia. Isoflurophate damages the acetylcholinesterase enzyme and is therefore irreversible, however, pralidoxime can displace organophosphates such as isoflurophate from acetylcholinesterase, but only if administered before isoflurophate damages (alkylates) the enzyme.
Mechanism of actionThe mechanism of isoflurophate's action involves the irreversible inhibition of cholinesterase.
TargetKindPharmacological actionActionsOrganismUniProt ID
AcetylcholinesteraseProteinyes
inhibitor
HumanP22303 details
CholinesteraseProteinyes
inhibitor
HumanP06276 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicitySigns of overdose include increased sweating, loss of bladder control, muscle weakness, nausea, vomiting, diarrhea, or stomach cramps or pain, shortness of breath, tightness in chest, or wheezing, slow or irregular heartbeat, unusual tiredness or weakness, watering of mouth.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Isoflurophate.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Isoflurophate.Experimental, Illicit
4-AndrostenedioneThe risk or severity of adverse effects can be increased when 4-Androstenedione is combined with Isoflurophate.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Isoflurophate.Experimental, Illicit
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Isoflurophate.Approved, Investigational
AcebutololIsoflurophate may increase the bradycardic activities of Acebutolol.Approved
AcetylcholineThe risk or severity of adverse effects can be increased when Isoflurophate is combined with Acetylcholine.Approved
AclidiniumThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Isoflurophate.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with Isoflurophate.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Isoflurophate.Experimental
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Isoflurophate.Approved, Investigational
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Isoflurophate.Approved, Illicit, Investigational
AlprenololIsoflurophate may increase the bradycardic activities of Alprenolol.Approved, Withdrawn
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Isoflurophate.Experimental
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Isoflurophate.Approved
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Isoflurophate.Illicit, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Isoflurophate.Approved
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Isoflurophate.Approved
AnecortaveThe risk or severity of adverse effects can be increased when Anecortave is combined with Isoflurophate.Investigational
Anisotropine MethylbromideThe therapeutic efficacy of Anisotropine Methylbromide can be decreased when used in combination with Isoflurophate.Approved
Aop200704Isoflurophate may increase the bradycardic activities of Aop200704.Investigational
ArecolineThe risk or severity of adverse effects can be increased when Isoflurophate is combined with Arecoline.Experimental
ArotinololIsoflurophate may increase the bradycardic activities of Arotinolol.Approved
AtenololIsoflurophate may increase the bradycardic activities of Atenolol.Approved
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Isoflurophate.Approved
Atracurium besylateThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Isoflurophate.Approved
AtropineThe therapeutic efficacy of Atropine can be decreased when used in combination with Isoflurophate.Approved, Vet Approved
BeclomethasoneThe risk or severity of adverse effects can be increased when Beclomethasone is combined with Isoflurophate.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Isoflurophate.Approved, Investigational
BefunololIsoflurophate may increase the bradycardic activities of Befunolol.Experimental
BenactyzineThe therapeutic efficacy of Benactyzine can be decreased when used in combination with Isoflurophate.Withdrawn
BenzatropineThe therapeutic efficacy of Benzatropine can be decreased when used in combination with Isoflurophate.Approved
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Isoflurophate.Approved, Vet Approved
BetaxololIsoflurophate may increase the bradycardic activities of Betaxolol.Approved
BethanecholThe risk or severity of adverse effects can be increased when Isoflurophate is combined with Bethanechol.Approved
BevantololIsoflurophate may increase the bradycardic activities of Bevantolol.Approved
BiperidenThe therapeutic efficacy of Biperiden can be decreased when used in combination with Isoflurophate.Approved
BisoprololIsoflurophate may increase the bradycardic activities of Bisoprolol.Approved
BoceprevirThe serum concentration of Isoflurophate can be decreased when it is combined with Boceprevir.Approved
BopindololIsoflurophate may increase the bradycardic activities of Bopindolol.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Isoflurophate.Approved, Investigational
BucindololIsoflurophate may increase the bradycardic activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Isoflurophate.Approved
BufuralolIsoflurophate may increase the bradycardic activities of Bufuralol.Experimental, Investigational
BupranololIsoflurophate may increase the bradycardic activities of Bupranolol.Approved
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Isoflurophate.Approved
CarbacholThe risk or severity of adverse effects can be increased when Isoflurophate is combined with Carbachol.Approved
CarbamazepineThe metabolism of Isoflurophate can be increased when combined with Carbamazepine.Approved, Investigational
CarteololIsoflurophate may increase the bradycardic activities of Carteolol.Approved
CarvedilolIsoflurophate may increase the bradycardic activities of Carvedilol.Approved, Investigational
CeliprololIsoflurophate may increase the bradycardic activities of Celiprolol.Approved, Investigational
CevimelineThe risk or severity of adverse effects can be increased when Isoflurophate is combined with Cevimeline.Approved
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Isoflurophate.Withdrawn
ChlorphenoxamineThe therapeutic efficacy of Chlorphenoxamine can be decreased when used in combination with Isoflurophate.Withdrawn
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Isoflurophate.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Isoflurophate.Approved, Investigational, Withdrawn
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Isoflurophate.Approved
ClobetasolThe risk or severity of adverse effects can be increased when Clobetasol is combined with Isoflurophate.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Isoflurophate.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Isoflurophate.Approved
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Isoflurophate.Approved, Vet Approved
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Isoflurophate.Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Isoflurophate.Approved
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Isoflurophate.Approved
CyclopentolateThe therapeutic efficacy of Cyclopentolate can be decreased when used in combination with Isoflurophate.Approved
CyclophosphamideThe risk or severity of adverse effects can be increased when Isoflurophate is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Isoflurophate.Approved, Investigational, Vet Approved
DarifenacinThe therapeutic efficacy of Darifenacin can be decreased when used in combination with Isoflurophate.Approved, Investigational
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Isoflurophate.Investigational
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Isoflurophate.Approved
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Isoflurophate.Approved
DesloratadineThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Isoflurophate.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Isoflurophate.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Isoflurophate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Isoflurophate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Isoflurophate.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Isoflurophate.Vet Approved
DexetimideThe therapeutic efficacy of Dexetimide can be decreased when used in combination with Isoflurophate.Withdrawn
DicyclomineThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Isoflurophate.Approved
DienestrolThe serum concentration of Dienestrol can be decreased when it is combined with Isoflurophate.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Isoflurophate.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Isoflurophate.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Isoflurophate.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Isoflurophate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Isoflurophate.Approved
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Isoflurophate.Approved
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Isoflurophate.Approved
DipyridamoleThe therapeutic efficacy of Isoflurophate can be decreased when used in combination with Dipyridamole.Approved
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Isoflurophate.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Isoflurophate.Approved
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Isoflurophate.Approved
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Isoflurophate.Approved, Investigational
EPIBATIDINEThe risk or severity of adverse effects can be increased when Isoflurophate is combined with EPIBATIDINE.Experimental
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with Isoflurophate.Experimental
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with Isoflurophate.Approved
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Isoflurophate.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Isoflurophate.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Isoflurophate.Approved
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Isoflurophate.Investigational
EsmololIsoflurophate may increase the bradycardic activities of Esmolol.Approved
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Isoflurophate.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Isoflurophate.Approved
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Isoflurophate.Approved
EstroneThe risk or severity of adverse effects can be increased when Estrone is combined with Isoflurophate.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Isoflurophate.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Isoflurophate.Approved
EthopropazineThe therapeutic efficacy of Ethopropazine can be decreased when used in combination with Isoflurophate.Approved
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Isoflurophate.Approved
FesoterodineThe therapeutic efficacy of Fesoterodine can be decreased when used in combination with Isoflurophate.Approved
fluasteroneThe risk or severity of adverse effects can be increased when fluasterone is combined with Isoflurophate.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Isoflurophate.Approved
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with Isoflurophate.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Flunisolide is combined with Isoflurophate.Approved, Investigational
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Isoflurophate.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Isoflurophate.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with Isoflurophate.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Isoflurophate.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with Isoflurophate.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with Isoflurophate.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Isoflurophate.Approved
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Isoflurophate.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Isoflurophate.Approved
FormestaneThe risk or severity of adverse effects can be increased when Formestane is combined with Isoflurophate.Approved, Investigational, Withdrawn
Gallamine TriethiodideThe therapeutic efficacy of Gallamine Triethiodide can be decreased when used in combination with Isoflurophate.Approved
GarlicThe serum concentration of Isoflurophate can be decreased when it is combined with Garlic.Approved
GlycopyrroniumThe therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Isoflurophate.Approved, Investigational, Vet Approved
GTS-21The risk or severity of adverse effects can be increased when Isoflurophate is combined with GTS-21.Investigational
HE3286The risk or severity of adverse effects can be increased when HE3286 is combined with Isoflurophate.Investigational
HexamethoniumThe therapeutic efficacy of Hexamethonium can be decreased when used in combination with Isoflurophate.Experimental
HexestrolThe serum concentration of Hexestrol can be decreased when it is combined with Isoflurophate.Withdrawn
HomatropineThe therapeutic efficacy of Homatropine can be decreased when used in combination with Isoflurophate.Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Isoflurophate.Approved, Vet Approved
HyoscyamineThe therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Isoflurophate.Approved
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Isoflurophate.Approved
IndenololIsoflurophate may increase the bradycardic activities of Indenolol.Withdrawn
Ipratropium bromideThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Isoflurophate.Approved
IstaroximeThe risk or severity of adverse effects can be increased when Istaroxime is combined with Isoflurophate.Investigational
LabetalolIsoflurophate may increase the bradycardic activities of Labetalol.Approved
LevobunololIsoflurophate may increase the bradycardic activities of Levobunolol.Approved
LobelineThe risk or severity of adverse effects can be increased when Isoflurophate is combined with Lobeline.Investigational
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Isoflurophate.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when ME-609 is combined with Isoflurophate.Investigational
MecamylamineThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Isoflurophate.Approved
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with Isoflurophate.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with Isoflurophate.Vet Approved
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Isoflurophate.Approved
MethacholineThe risk or severity of adverse effects can be increased when Isoflurophate is combined with Methacholine.Approved
MethallenestrilThe serum concentration of Methallenestril can be decreased when it is combined with Isoflurophate.Experimental
MethanthelineThe therapeutic efficacy of Methantheline can be decreased when used in combination with Isoflurophate.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Isoflurophate.Approved, Vet Approved
MetipranololIsoflurophate may increase the bradycardic activities of Metipranolol.Approved
MetixeneThe therapeutic efficacy of Metixene can be decreased when used in combination with Isoflurophate.Approved
MetoprololIsoflurophate may increase the bradycardic activities of Metoprolol.Approved, Investigational
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Isoflurophate.Approved, Illicit
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Isoflurophate.Approved
MivacuriumIsoflurophate may decrease the neuromuscular blocking activities of Mivacurium.Approved
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with Isoflurophate.Approved, Vet Approved
N-butylscopolammonium bromideThe therapeutic efficacy of N-butylscopolammonium bromide can be decreased when used in combination with Isoflurophate.Vet Approved
NadololIsoflurophate may increase the bradycardic activities of Nadolol.Approved
NCX 1022The risk or severity of adverse effects can be increased when NCX 1022 is combined with Isoflurophate.Investigational
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Isoflurophate.Approved, Withdrawn
NicotineThe risk or severity of adverse effects can be increased when Isoflurophate is combined with Nicotine.Approved
Nicotine bitartrateThe risk or severity of adverse effects can be increased when Isoflurophate is combined with Nicotine bitartrate.Approved
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Isoflurophate.Approved
NVA237The therapeutic efficacy of NVA237 can be decreased when used in combination with Isoflurophate.Investigational
Oleoyl estroneThe risk or severity of adverse effects can be increased when Oleoyl estrone is combined with Isoflurophate.Investigational
OpipramolThe serum concentration of Opipramol can be increased when it is combined with Isoflurophate.Investigational
OrphenadrineThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with Isoflurophate.Approved
OxprenololIsoflurophate may increase the bradycardic activities of Oxprenolol.Approved
OxybutyninThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Isoflurophate.Approved, Investigational
OxyphenoniumThe therapeutic efficacy of Oxyphenonium can be decreased when used in combination with Isoflurophate.Approved
PancuroniumThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Isoflurophate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Isoflurophate.Approved
PenbutololIsoflurophate may increase the bradycardic activities of Penbutolol.Approved, Investigational
PentoliniumThe therapeutic efficacy of Pentolinium can be decreased when used in combination with Isoflurophate.Approved
PethidineThe risk or severity of adverse effects can be increased when Isoflurophate is combined with Pethidine.Approved
PilocarpineThe risk or severity of adverse effects can be increased when Isoflurophate is combined with Pilocarpine.Approved
PimozideThe serum concentration of Pimozide can be increased when it is combined with Isoflurophate.Approved
PindololIsoflurophate may increase the bradycardic activities of Pindolol.Approved
PipecuroniumThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Isoflurophate.Approved
PirenzepineThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Isoflurophate.Approved
PractololIsoflurophate may increase the bradycardic activities of Practolol.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Isoflurophate.Approved, Nutraceutical
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Isoflurophate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Isoflurophate.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Isoflurophate.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Isoflurophate.Experimental
ProcyclidineThe therapeutic efficacy of Procyclidine can be decreased when used in combination with Isoflurophate.Approved
PropanthelineThe therapeutic efficacy of Propantheline can be decreased when used in combination with Isoflurophate.Approved
PropiverineThe therapeutic efficacy of Propiverine can be decreased when used in combination with Isoflurophate.Investigational
PropranololIsoflurophate may increase the bradycardic activities of Propranolol.Approved, Investigational
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Isoflurophate.Approved
QuinidineThe therapeutic efficacy of Quinidine can be decreased when used in combination with Isoflurophate.Approved
RapacuroniumIsoflurophate may decrease the neuromuscular blocking activities of Rapacuronium.Withdrawn
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Isoflurophate.Approved
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Isoflurophate.Approved
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Isoflurophate.Approved
ScopolamineThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Isoflurophate.Approved
Scopolamine butylbromideThe therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Isoflurophate.Approved
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Isoflurophate.Approved, Investigational
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Isoflurophate.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Isoflurophate.Approved
SolifenacinThe therapeutic efficacy of Solifenacin can be decreased when used in combination with Isoflurophate.Approved
SotalolIsoflurophate may increase the bradycardic activities of Sotalol.Approved
St. John's WortThe metabolism of Isoflurophate can be increased when combined with St. John's Wort.Nutraceutical
SuccinylcholineThe serum concentration of Succinylcholine can be increased when it is combined with Isoflurophate.Approved
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Isoflurophate.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Isoflurophate.Approved, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Isoflurophate is combined with Temsirolimus.Approved
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Isoflurophate.Approved
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Isoflurophate.Approved
TimololIsoflurophate may increase the bradycardic activities of Timolol.Approved
TiotropiumThe therapeutic efficacy of Tiotropium can be decreased when used in combination with Isoflurophate.Approved
TipranavirThe serum concentration of Isoflurophate can be decreased when it is combined with Tipranavir.Approved, Investigational
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with Isoflurophate.Approved
TolterodineThe therapeutic efficacy of Tolterodine can be decreased when used in combination with Isoflurophate.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Isoflurophate.Approved, Vet Approved
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Isoflurophate.Approved
TrihexyphenidylThe therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Isoflurophate.Approved
TrimethaphanThe therapeutic efficacy of Trimethaphan can be decreased when used in combination with Isoflurophate.Approved
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Isoflurophate.Approved
TropicamideThe therapeutic efficacy of Tropicamide can be decreased when used in combination with Isoflurophate.Approved
TrospiumThe therapeutic efficacy of Trospium can be decreased when used in combination with Isoflurophate.Approved
TubocurarineThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Isoflurophate.Approved
UmeclidiniumThe therapeutic efficacy of Umeclidinium can be decreased when used in combination with Isoflurophate.Approved
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Isoflurophate.Approved, Investigational
VareniclineThe risk or severity of adverse effects can be increased when Isoflurophate is combined with Varenicline.Approved, Investigational
VecuroniumThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Isoflurophate.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Isoflurophate.Approved
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Isoflurophate.Approved
Food InteractionsNot Available
References
Synthesis Reference

U.S. Patent 2,409,039.

General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (57.7 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9971
Blood Brain Barrier+0.9803
Caco-2 permeable-0.5386
P-glycoprotein substrateNon-substrate0.8483
P-glycoprotein inhibitor INon-inhibitor0.7683
P-glycoprotein inhibitor IINon-inhibitor0.9518
Renal organic cation transporterNon-inhibitor0.9541
CYP450 2C9 substrateNon-substrate0.8393
CYP450 2D6 substrateNon-substrate0.8447
CYP450 3A4 substrateNon-substrate0.5232
CYP450 1A2 substrateNon-inhibitor0.8174
CYP450 2C9 inhibitorNon-inhibitor0.8396
CYP450 2D6 inhibitorNon-inhibitor0.9132
CYP450 2C19 inhibitorNon-inhibitor0.7248
CYP450 3A4 inhibitorNon-inhibitor0.8834
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9185
Ames testNon AMES toxic0.8082
CarcinogenicityCarcinogens 0.8124
BiodegradationNot ready biodegradable0.8938
Rat acute toxicity4.5346 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9572
hERG inhibition (predictor II)Non-inhibitor0.8508
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Merck and co inc
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateLiquid
Experimental Properties
PropertyValueSource
boiling point62 @ 9mm, 46 @ 5mmU.S. Patent 2,409,039.
water solubility1.54E+004 mg/L (at 25 °C)MERCK INDEX (1996)
logP1.17CZERWINSKI,SE ET AL. (1998)
Predicted Properties
PropertyValueSource
Water Solubility6.78 mg/mLALOGPS
logP1.1ALOGPS
logP1.76ChemAxon
logS-1.4ALOGPS
pKa (Strongest Basic)-9.6ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area35.53 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity40.89 m3·mol-1ChemAxon
Polarizability16.75 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phosphate esters. These are organic compounds containing phosphoric acid ester functional group, with the general structure R1P(=O)(R2)OR3. R1,R2 = O,N, or halogen atom; R3 = organyl group.
KingdomOrganic compounds
Super ClassOrganophosphorus compounds
ClassOrganic phosphoric acids and derivatives
Sub ClassPhosphate esters
Direct ParentPhosphate esters
Alternative Parents
Substituents
  • Phosphoric acid ester
  • Hydrocarbon derivative
  • Organooxygen compound
  • Aliphatic acyclic compound
Molecular FrameworkAliphatic acyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serine hydrolase activity
Specific Function:
Terminates signal transduction at the neuromuscular junction by rapid hydrolysis of the acetylcholine released into the synaptic cleft. Role in neuronal apoptosis.
Gene Name:
ACHE
Uniprot ID:
P22303
Molecular Weight:
67795.525 Da
References
  1. Malatova Z, Gottlieb M, Marsala J: Depression of acetylcholinesterase synthesis following transient cerebral ischemia in rat: pharmacohistochemical and biochemical investigation. Gen Physiol Biophys. 1999 Mar;18(1):57-71. [PubMed:10378121 ]
  2. Quistad GB, Zhang N, Sparks SE, Casida JE: Phosphoacetylcholinesterase: toxicity of phosphorus oxychloride to mammals and insects that can be attributed to selective phosphorylation of acetylcholinesterase by phosphorodichloridic acid. Chem Res Toxicol. 2000 Jul;13(7):652-7. [PubMed:10898598 ]
  3. da Costa VL Jr, Lapa AJ, Godinho RO: Short- and long-term influences of calcitonin gene-related peptide on the synthesis of acetylcholinesterase in mammalian myotubes. Br J Pharmacol. 2001 May;133(2):229-36. [PubMed:11350858 ]
  4. Pang YP, Kollmeyer TM, Hong F, Lee JC, Hammond PI, Haugabouk SP, Brimijoin S: Rational design of alkylene-linked bis-pyridiniumaldoximes as improved acetylcholinesterase reactivators. Chem Biol. 2003 Jun;10(6):491-502. [PubMed:12837382 ]
  5. Ashani Y, Gentry MK, Doctor BP: Differences in conformational stability between native and phosphorylated acetylcholinesterase as evidenced by a monoclonal antibody. Biochemistry. 1990 Mar 13;29(10):2456-63. [PubMed:1692236 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Identical protein binding
Specific Function:
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name:
BCHE
Uniprot ID:
P06276
Molecular Weight:
68417.575 Da
References
  1. Kamata R, Saito S, Suzuki T, Takewaki T, Kobayashi H: Correlation of binding sites for diisopropyl phosphorofluoridate with cholinesterase and neuropathy target esterase in membrane and cytosol preparations from hen. Neurotoxicology. 2001 Apr;22(2):203-14. [PubMed:11405252 ]
  2. Acey RA, Bailey S, Healy P, Jo C, Unger TF, Hudson RA: A butyrylcholinesterase in the early development of the brine shrimp (Artemia salina) larvae: a target for phthalate ester embryotoxicity? Biochem Biophys Res Commun. 2002 Dec 13;299(4):659-62. [PubMed:12459190 ]
  3. Pittel Z, Cohen S, Fisher A, Heldman E: Differential long-term effect of AF64A on [3H]ACh synthesis and release in rat hippocampal synaptosomes. Brain Res. 1992 Jul 17;586(1):148-51. [PubMed:1511344 ]
  4. Miller RB, Blank CL: Determination of serum cholinesterase activity by liquid chromatography with electrochemical detection. Anal Biochem. 1991 Aug 1;196(2):377-84. [PubMed:1776688 ]
  5. Kelly SS, Ferry CB, Bamforth JP: The effects of anticholinesterases on the latencies of action potentials in mouse skeletal muscles. Br J Pharmacol. 1990 Apr;99(4):721-6. [PubMed:2361169 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Identical protein binding
Specific Function:
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name:
BCHE
Uniprot ID:
P06276
Molecular Weight:
68417.575 Da
References
  1. Kamata R, Saito S, Suzuki T, Takewaki T, Kobayashi H: Correlation of binding sites for diisopropyl phosphorofluoridate with cholinesterase and neuropathy target esterase in membrane and cytosol preparations from hen. Neurotoxicology. 2001 Apr;22(2):203-14. [PubMed:11405252 ]
  2. Acey RA, Bailey S, Healy P, Jo C, Unger TF, Hudson RA: A butyrylcholinesterase in the early development of the brine shrimp (Artemia salina) larvae: a target for phthalate ester embryotoxicity? Biochem Biophys Res Commun. 2002 Dec 13;299(4):659-62. [PubMed:12459190 ]
  3. Pittel Z, Cohen S, Fisher A, Heldman E: Differential long-term effect of AF64A on [3H]ACh synthesis and release in rat hippocampal synaptosomes. Brain Res. 1992 Jul 17;586(1):148-51. [PubMed:1511344 ]
  4. Miller RB, Blank CL: Determination of serum cholinesterase activity by liquid chromatography with electrochemical detection. Anal Biochem. 1991 Aug 1;196(2):377-84. [PubMed:1776688 ]
  5. Kelly SS, Ferry CB, Bamforth JP: The effects of anticholinesterases on the latencies of action potentials in mouse skeletal muscles. Br J Pharmacol. 1990 Apr;99(4):721-6. [PubMed:2361169 ]
  6. Masson P, Fortier PL, Albaret C, Froment MT, Bartels CF, Lockridge O: Aging of di-isopropyl-phosphorylated human butyrylcholinesterase. Biochem J. 1997 Oct 15;327 ( Pt 2):601-7. [PubMed:9359435 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23